Article Text

other Versions

Download PDFPDF
Recurrence risk after sentinel lymph node biopsy in patients with early cervical cancer: Follow-up results after 3 years of a prospective study (SENTICOL)
  1. Benedetta Guani1,
  2. Maxence Dorez2,
  3. Laurent Magaud3,4,
  4. Annie Buenerd5,
  5. Fabrice Lecuru6 and
  6. Patrice Mathevet1,7
  1. 1CHUV, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
  2. 2CHU de l'Archet 2, Nice, France
  3. 3Public Health Department, Hospices Civils de Lyon, Lyon, France
  4. 4Univ Lyon, EA 7425 HESPER, Health Services and Performance Research, Lyon, France
  5. 5Service d'anatomopathologie, Hôpital femme-mère-enfant, Bron, France
  6. 6Hôpital Européen George Pompidou, Paris, France
  7. 7UNIL, Université de Lausanne, Lausanne, Switzerland
  1. Correspondence to Patrice Mathevet, UNIL, Université de Lausanne, Lausanne 1015, Switzerland; patrice.mathevet{at}chuv.ch

Abstract

This prospective study is a 3-year follow-up of patients included in the prospective longitudinal SENTICOL (Ganglion Sentinelle dans le Cancer du Col) study.

Objectives The primary outcome was disease-free survival; the secondary outcome was the predictive value of the presence of micrometastasis and isolated tumor cells for recurrence.

Methods The study included patients with cervical carcinoma FIGO (International Federation of Gynecology and Obstetrics) stage IA1 with lymphovascular space invasion, stage IA2 and IB1, who participated in the prospective SENTICOL study. A centralized histological analysis with re-reading and ultrastaging was performed 3 months after the interventions; discovery of micrometastasis or isolated tumor cells in the sentinel and non-sentinel lymph nodes did not change the treatment that was previously planned. Patients were followed up after 3 years. Results were compared according to prognostic factors.

Results We found 13 recurrences during the 3-year follow-up: two recurrences in patients with positive sentinel lymph nodes (one macrometastasis and one micrometastasis) and 11 recurrences in patients with negative lymph nodes (sentinel lymph nodes and non-sentinel lymph nodes). There was no statistically significant difference in disease-free survival in terms of prognostic factors in our cohort, except patient age: we found a significant decrease in disease-free survival in patients >50 years old (p=0.01).

Among patients with sentinel lymph nodes positive for micrometastasis, only one had a recurrence (negative predictive value 89%).

Conclusions Unlike previous retrospective studies, this prospective study showed no impact of micrometastasis or isolated tumor cells in sentinel lymph nodes on disease-free survival. However, due to the relatively short follow-up, some late recurrences may have been missed.

  • cervical cancer
  • sentinel lymph node
  • micrometastasis
  • isolated tumor cells
View Full Text

Statistics from Altmetric.com

Footnotes

  • Funding Funded by the French national cancer institute (PHRC 2004).

  • Competing interests None declared.

  • Provenance and peer review Not commissioned, externally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles